We are Zogenix.Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.
A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products through industry-leading initiatives to educate patients, healthcare providers and pharmacists.
We recognize the public health concerns around the misuse and abuse of prescription medicines and are fully committed to responsible leadership, in partnership with all stakeholders, to develop solutions that have a real impact on the appropriate and safe use of our medicines.
Zogenix represents the intersection of where medicine meets technology. We were established in 2006 by an experienced pharmaceutical commercial leader who launched multiple new therapies including sumatriptan injection in 1993 and by an experienced pharmaceutical scientist who has developed multiple drug delivery technologies including DosePro.
Innovation is key to our success. In 2010, we were honored to receive the Most Innovative Product Award in the Life Sciences category from CONNECT. We take pride in our approach to product development, commercialization strategy and delivering results.
But mostly, we take pride in our employees and how we conduct our business on a daily basis.
We are Zogenix.